Temozolomide
- Generic Name
- Temozolomide
- Brand Names
- Temodar, Temomedac, Temodal, Temozolomide Sun, Temozolomide Accord, Temozolomide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C6H6N6O2
- CAS Number
- 85622-93-1
- Unique Ingredient Identifier
- YF1K15M17Y
- Background
Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably ...
- Indication
Temozolomide is indicated in adult patients for the treatment of newly diagnosed glioblastoma concomitantly with radiotherapy and for use as maintenance treatment thereafter. It is also indicated for the treatment of refractory anaplastic astrocytoma in adult patients or adjuvant therapy for adults with newly diagnosed anaplastic astrocytoma.
- Associated Conditions
- Advanced Melanoma, High Grade Glioma: Glioblastoma (GBM), Primary Central Nervous System Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Soft Tissue Sarcoma, Advanced Neuroendocrine tumor, Newly diagnosed Anaplastic Astrocytoma (AA), Refractory Anaplastic astrocytoma, Refractory, advanced Mycosis fungoides, Refractory, advanced Sezary Syndrome
- Associated Therapies
- -
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 60
- Registration Number
- NCT05236036
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Chlorpromazine and Standard of Care in Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-13
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Mohammed Milhem
- Target Recruit Count
- 10
- Registration Number
- NCT05190315
- Locations
- 🇺🇸
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT05142241
- Locations
- 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2023-03-01
- Target Recruit Count
- 21
- Registration Number
- NCT05136326
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT05128734
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Yong Chen
- Target Recruit Count
- 31
- Registration Number
- NCT05106023
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05096481
- Locations
- 🇺🇸
Duke Cancer Center, Durham, North Carolina, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸St. Louis Children's Hospital, Saint Louis, Missouri, United States
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 306
- Registration Number
- NCT05095376
- Locations
- 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸Mercy Cancer Center - Carmichael, Carmichael, California, United States
🇺🇸John Muir Medical Center-Concord, Concord, California, United States
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2024-11-06
- Target Recruit Count
- 50
- Registration Number
- NCT05083754
- Locations
- 🇺🇸
Johns Hopkins Medical Institution, Baltimore, Maryland, United States
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Leland Metheny
- Target Recruit Count
- 16
- Registration Number
- NCT05052957
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.